Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this trial is to determine the safety and efficacy of Imiquimod, a Toll-like receptor 7 agonist in breast cancer (for chestwall recurrences or metastases to the skin).
| Condition | Intervention | Phase |
|---|---|---|
|
Breast Cancer Breast Neoplasms |
Drug: Imiquimod |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase II Evaluation of Imiquimod, a Topical Toll-like Receptor 7 (TLR7) Agonist in Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases |
- Objective Response (Complete Clinical Response+ Partial Response) [ Time Frame: 9 weeks ] [ Designated as safety issue: No ]This is defined as percentage of patients who achieved complete clinical response or partial response at end of cycle 1 of treatment. The tumor size will be measured as lesion surface area (region of interest, ROI). The response to the treatment is then evaluated as a function of post-treatment over pre-treatment ROI, expressed in percentage. Response criteria for this study are based on European Organisation for Research and Treatment of Cancer definitions for chest wall tumors: complete clinical response: absence of any detectable residual disease; partial response: <50% of ROI change.
- Clinical Benefits [ Time Frame: 9 weeks ] [ Designated as safety issue: No ]This outcome measure is defined as number of patients with improvement of symptoms after 8 weeks of treatment.
| Enrollment: | 10 |
| Study Start Date: | May 2009 |
| Study Completion Date: | November 2013 |
| Primary Completion Date: | April 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Imiquimod
Each treatment cycle consists of 8 weeks. Weeks 1-8: day 1-5 of each week: 1 packet imiquimod 5% cream applied overnight, day 6-7 of each week: rest period. Patients with responding or stable local disease (non-progressors) may continue to receive treatment following the same schedule (as outlined above for the first cycle) until complete tumor regression, unacceptable toxicity or progression of disease. |
Drug: Imiquimod
Each treatment cycle consists of 8 weeks. Weeks 1-8: day 1-5 of each week: 1 packet imiquimod 5% cream applied overnight, day 6-7 of each week: rest period. Patients with responding or stable local disease (non-progressors) may continue to receive treatment following the same schedule (as outlined above for the first cycle) until complete tumor regression, unacceptable toxicity or progression of disease. Other Name: Aldara
|
Detailed Description:
TLR agonists are novel agents for cancer therapy which modify the immune response. Imiquimod, a synthetic TLR7 agonist has proven immunomodulatory activity when applied topically, leading to clearance of human papilloma virus (HPV)-induced genital warts and primary skin malignancies. Its effects will now be examined in breast cancer metastatic to the skin. If effective, it will add a relatively non-toxic approach to the treatment armamentarium for this patient population frequently resistant to conventional therapies.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with biopsy-confirmed breast cancer (prior histological documentation is acceptable).
- Patients with measurable skin metastases (chest wall recurrence and/or non-chest wall skin metastases are eligible).
- Skin metastases not suitable for or patient refusing definitive surgical resection and radiation.
- (Cohort 1) Concurrent systemic cancer therapy (hormones, biologics or chemotherapy) is allowed if distant metastases have been non-progressing (stable or responding) on that regimen for > or = 12 weeks and skin metastases are non-responsive (stable or progressing) as assessed by the investigator.
(Cohort 2) Any concurrent systemic therapy is allowed
- Age at least 18 years.
- Eastern Cooperative Oncology Group (ECOG) performance status < or = 2.
- Patients must have biopsy-accessible tumor (skin metastases) and agree to biopsies required by protocol.
-
Patients must have adequate organ and bone marrow function as defined below:
- absolute neutrophil count > or = 1,500/microliter
- hemoglobin > or = 9.5 grams/deciliter
- platelets >or = 75,000/microliter
- total bilirubin < or = 1.5 X institutional upper limit of normal
- Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) < or = 2.5X institutional upper limit of normal
- creatinine < or = 1.5 X institutional upper limit of normal
- Informed consent.
Exclusion Criteria:
- Brain metastases unless resected or irradiated and stable > or = 8 weeks.
- Treatment with other investigational agents.
- Patients who have received radiotherapy, high-potency corticosteroids, intralesional therapy, laser therapy or surgery other than biopsy to the target area within 4 weeks prior to first dosing of study agent.
- Patients who have received hyperthermia to the target area within 10 weeks prior to first dosing of study agent.
- Patients with an uncontrolled bleeding disorder.
- Patients who will be therapeutically anticoagulated with heparins or coumadin at the time of the biopsy (they are eligible if anticoagulation can be held prior to biopsy as per investigator). Patients on aspirin and other platelet agents are eligible.
- Patients with known immunodeficiency or receiving immunosuppressive therapies.
- History of allergic reactions to imiquimod or its excipients.
- Uncontrolled intercurrent medical illness or psychiatric illness/social situations that would limit compliance with study requirements.
- Pregnancy or lactation.
- Women of childbearing potential not using a medically acceptable means of contraception.
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00899574
| United States, New York | |
| NYU Cancer Institute | |
| New York, New York, United States, 10016 | |
| Principal Investigator: | Sylvia Adams, MD | New York University School of Medicine |
More Information
Publications:
| Responsible Party: | New York University School of Medicine |
| ClinicalTrials.gov Identifier: | NCT00899574 History of Changes |
| Other Study ID Numbers: | NYU 09-0225 |
| Study First Received: | May 11, 2009 |
| Results First Received: | April 12, 2012 |
| Last Updated: | August 19, 2014 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by New York University School of Medicine:
|
toll-like receptor toll-like receptor agonist recurrent breast cancer breast cancer metastasized to skin and/or chestwall immunomodulator |
Additional relevant MeSH terms:
|
Breast Neoplasms Breast Diseases Neoplasms Neoplasms by Site Skin Diseases Imiquimod Adjuvants, Immunologic |
Antineoplastic Agents Immunologic Factors Interferon Inducers Pharmacologic Actions Physiological Effects of Drugs Therapeutic Uses |
ClinicalTrials.gov processed this record on March 01, 2015